These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15776130)

  • 1. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.
    Nguyen VH; Peloquin S; Lacasse Y
    Can Respir J; 2005; 12(1):19-25. PubMed ID: 15776130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
    J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.
    Alzahouri K; Lejeune C; Woronoff-Lemsi MC; Arveux P; Guillemin F
    Clin Radiol; 2005 Apr; 60(4):479-92. PubMed ID: 15767106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
    Scott WJ; Shepherd J; Gambhir SS
    Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
    Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
    Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
    Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.
    Dietlein M; Weber K; Gandjour A; Moka D; Theissen P; Lauterbach KW; Schicha H
    Eur J Nucl Med; 2000 Nov; 27(11):1598-609. PubMed ID: 11105815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
    Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
    Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?
    Hayashi K; Abe K; Yano F; Watanabe S; Iwasaki Y; Kosuda S
    Ann Nucl Med; 2005 Jul; 19(5):393-8. PubMed ID: 16164196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of the cost-effectiveness of positron-emission tomography in staging of non--small-cell lung cancer and management of solitary pulmonary nodules.
    Cao JQ; Rodrigues GB; Louie AV; Zaric GS
    Clin Lung Cancer; 2012 May; 13(3):161-70. PubMed ID: 22133290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
    Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
    J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness of PET in the management algorithms of lung tumors: comparison of health economic data].
    Dietlein M; Moka D; Weber K; Theissen P; Schicha H
    Nuklearmedizin; 2001 Aug; 40(4):122-8. PubMed ID: 11556202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is positron emission tomography for the management of potentially operable non-small cell lung cancer an efficient use of Quebec health care resources?
    Lamy A; Gafni A
    Can Respir J; 2005; 12(1):11-2. PubMed ID: 15776128
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost effectiveness of chest computed tomography after lung cancer resection: a decision analysis model.
    Kent MS; Korn P; Port JL; Lee PC; Altorki NK; Korst RJ
    Ann Thorac Surg; 2005 Oct; 80(4):1215-22; discussion 1222-3. PubMed ID: 16181843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staging non-small lung cancer with positron emission tomography: diagnostic value, impact on patient management, and cost-effectiveness.
    Nosotti M; Castellani M; Longari V; Chella B; Baisi A; Rosso L; Santambrogio L
    Int Surg; 2008; 93(5):278-83. PubMed ID: 19943430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada.
    Sloka JS; Hollett PD; Mathews M
    Med Sci Monit; 2004 May; 10(5):MT73-80. PubMed ID: 15114279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET/CT in non-small cell lung cancer staging-promises and problems.
    Devaraj A; Cook GJ; Hansell DM
    Clin Radiol; 2007 Feb; 62(2):97-108. PubMed ID: 17207691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.